Somapacitan + Norditropin®
Phase 2Active 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Short Stature Children Born Small for Gestational Age (SGA)
Conditions
Short Stature Children Born Small for Gestational Age (SGA)
Trial Timeline
Jul 4, 2019 → Dec 23, 2026
NCT ID
NCT03878446About Somapacitan + Norditropin®
Somapacitan + Norditropin® is a phase 2 stage product being developed by Novo Nordisk for Short Stature Children Born Small for Gestational Age (SGA). The current trial status is active. This product is registered under clinical trial identifier NCT03878446. Target conditions include Short Stature Children Born Small for Gestational Age (SGA).
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05330325 | Phase 3 | Active |
| NCT04970654 | Phase 3 | Completed |
| NCT03878446 | Phase 2 | Active |
| NCT03811535 | Phase 3 | Completed |
Competing Products
20 competing products in Short Stature Children Born Small for Gestational Age (SGA)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| somatropin + leuprorelin | Eli Lilly | Phase 3 | 77 |
| Growth Hormone | Eli Lilly | Approved | 85 |
| Pancreatic Enzyme | AbbVie | Phase 2 | 52 |
| Aromatase Inhibitor + Growth Hormone + Aromatase Inhibitor and Growth Hormone | AstraZeneca | Phase 3 | 77 |
| Oral, live, pentavalent rotavirus vaccine; RotaTeq(R) | Merck | Phase 1 | 33 |
| Saizen® + Saizen® | Merck | Phase 3 | 77 |
| r-metHuLeptin | Amgen | Phase 1 | 32 |
| Somatotropin growth hormone recombinant human | Pfizer | Approved | 84 |
| Genotropin (somatropin) | Pfizer | Approved | 84 |
| Genotropin + Genotropin | Pfizer | Phase 3 | 76 |
| GH treatment (Genotropin) + 1 year treatment with placebo followed by optional 3 years of GH treatment | Pfizer | Approved | 84 |
| Genotropin | Pfizer | Phase 2/3 | 64 |
| glepaglutide | Zealand Pharma | Phase 3 | 74 |
| Glepaglutide | Zealand Pharma | Phase 3 | 74 |
| ZP1848 | Zealand Pharma | Phase 2 | 49 |
| glepaglutide + Placebo | Zealand Pharma | Phase 3 | 74 |
| Glepaglutide | Zealand Pharma | Phase 3 | 74 |
| Glepaglutide 10 mg | Zealand Pharma | Phase 3 | 74 |
| Glepaglutide | Zealand Pharma | Phase 3 | 74 |
| Nutropin [Somatropin (rDNA origin) for injection] | Ipsen | Approved | 82 |